person · Reporting owner
Gutierrez-Ramos Jose-Carlos
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | January 02, 2026 | January 07, 2026 |
| DANAHER CORP /DE/DHR · Entity 2871 | SVP, Chief Science Officer | August 04, 2026 | August 06, 2026 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 08, 2023 | June 12, 2023 |
| SYNLOGIC, INC.SYBX · Entity 7801 | Director · See Remarks | March 14, 2018 | March 16, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 32,500 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 9,500 · Balance 32,500 F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2: Each RSU represents a contingent right to receive one ordinary share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2036-01-02 | Direct | 19,000 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 19,000 · Balance 19,000 F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
DANAHER CORP /DE/
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,495 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Grant · Acquired 13,477 · Balance 32,495 F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated in connection with the Issuer's Long-Term Growth Program, as previously reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2026. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One hundred percent of the RSUs vest on the 12-month anniversary of the grant date, which is August 4, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated in connection with the Issuer's Long-Term Growth Program, as previously reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2026. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One hundred percent of the RSUs vest on the 12-month anniversary of the grant date, which is August 4, 2026.
Evelo Biosciences, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08 | Direct | 20,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant.
SYNLOGIC, INC.
Report date March 14, 2018 · Filed March 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-03-14 | Direct | 120,540 |
Reported balance
After 2018-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-14 · Grant · Acquired 120,540 · Balance 120,540 F1: The options vest and become exercisable in substantially equal monthly installments beginning on April 14, 2018 and continuing until March 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable in substantially equal monthly installments beginning on April 14, 2018 and continuing until March 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2026-03-09 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 11,207 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 8,855 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2020 Filed Oct 1, 2020 21:17 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $12.64 | Not disclosed |
DisclosureSEC source: 0001179110-20-010063 · edgar.xml · derivative · entry 4 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:17 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,855 | Not disclosed Strike: $22.30 | Not disclosed |
DisclosureSEC source: 0001179110-20-010063 · edgar.xml · derivative · entry 3 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,855 shares Expires 2028-06-20 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:17 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,207 | Not disclosed Strike: $17.20 | Not disclosed |
DisclosureSEC source: 0001179110-20-010063 · edgar.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,207 shares Expires 2027-06-20 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:17 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $8.59 | Not disclosed |
DisclosureSEC source: 0001179110-20-010063 · edgar.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-03-09 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 22:19 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001179110-20-009202 · edgar.xml · derivative · entry 3 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 22:19 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 10,000 | $52.09 | $520,900.00 |
DisclosureSEC source: 0001179110-20-009202 · edgar.xml · nonDerivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 22:19 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 10,000 | $8.59 | $85,900.00 |
DisclosureSEC source: 0001179110-20-009202 · edgar.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:46 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $38.09 | $0.00 |
DisclosureSEC source: 0001179110-20-007755 · edgar.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr.Gutierrez-Ramos' continued service to the Company. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 22:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 4,356 | $29.09 | $126,716.04 |
DisclosureSEC source: 0001179110-20-000729 · edgar.xml · nonDerivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $28.81 to $30.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 22:14 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 5,734 | $29.10 | $166,859.40 |
DisclosureSEC source: 0001179110-20-000729 · edgar.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,356 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.78 to $29.845. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Unit · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008022 · edgar.xml · derivative · entry 3 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F3 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008022 · edgar.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001179110-19-008022 · edgar.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr.Gutierrez-Ramos' continued service to the Company. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:27 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 31,380 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001694665-19-000055 · wf-form4_156054401621064.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,380 Underlying: Common Stock · 31,380 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments following the award grant date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:50 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008965 · edgar.xml · derivative · entry 4 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. F5 · derivative.expiration_date: Subject to certain criteria, 100% of the restricted stock units shall vest on the first anniversary of the grant date. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:50 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 4,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008965 · edgar.xml · derivative · entry 3 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,356 Underlying: Common Stock · 4,356 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gutierrez-Ramos' continued service to the Company. F3 · derivative.expiration_date: Represents 4,356 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gutierrez-Ramos' continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:50 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 8,855 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0001179110-18-008965 · edgar.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Underlying: Common Stock · 8,855 shares Expires 2028-06-20 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Gutierrez-Ramos' continued service to the Company. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:50 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Exercise / conversionCommon Stock | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008965 · edgar.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 10:05 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 120,540 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0000899243-18-007675 · doc4.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,540 Underlying: Common Stock · 120,540 shares Expires 2028-03-14 F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal monthly installments beginning on April 14, 2018 and continuing until March 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. Read SEC document |
| October 02, 2017 Filed Feb 13, 2018 21:32 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-003687 · doc5.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,619 F1 · shares: This Report relates to a gift of 10,000 shares of common stock made by the Reporting Person on October 2, 2017. The gifted shares were fully vested as of the date of the gift in accordance with the vesting schedule described in footnote 2. F2 · balance_after: Pursuant to the terms of a restricted stock agreement by and between the Issuer and the Reporting Person, one-fourth of the total number of shares originally granted pursuant to the restricted stock agreement vested on May 14, 2016, with the remainder vesting in equal monthly installments until May 14, 2019, provided that at the relevant vesting dates the Reporting Person continues service to the Issuer and has not been terminated as defined in, and as determined under, the Issuer's 2017 Stock Incentive Plan. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:04 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantRestricted Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009448 · edgar.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Underlying: Common Stock · 5,734 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNTA common stock. F3 · derivative.exercise_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gutierrez-Ramos' continued service to the Company. F3 · derivative.expiration_date: Represents 5,734 restricted stock units, awarded pursuant to the Company's 2013 Incentive Award Plan, 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Dr. Gutierrez-Ramos' continued service to the Company. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:04 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 11,207 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001179110-17-009448 · edgar.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,207 Underlying: Common Stock · 11,207 shares Expires 2027-06-20 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Gutierrez-Ramos' continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.